Immediate Impact
60 standout
Citing Papers
Cancer statistics, 2024
2024 Standout
Exploiting the therapeutic implications of KRAS inhibition on tumor immunity
2024 Standout
Works of Changli Wang being referenced
Clinical outcomes with neoadjuvant nivolumab (N) + chemotherapy (C) vs C by definitive surgery in patients (pts) with resectable NSCLC: 3-y results from the phase 3 CheckMate 816 trial.
2023
Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice
2011
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Changli Wang | 441 | 339 | 112 | 28 | 507 | |
| Samir Darwish | 303 | 247 | 85 | 16 | 433 | |
| M. Lomas | 354 | 408 | 52 | 22 | 504 | |
| Serena Ricciardi | 280 | 338 | 57 | 27 | 531 | |
| M.R. Migliorino | 497 | 404 | 61 | 39 | 549 | |
| Jean-François Martini | 365 | 220 | 125 | 24 | 445 | |
| Jean‐Marc Verdebout | 297 | 314 | 76 | 21 | 474 | |
| Kensuke Nakazawa | 263 | 269 | 63 | 30 | 466 | |
| Carol A. Sherman | 370 | 315 | 55 | 28 | 545 | |
| Shanbo Zheng | 343 | 197 | 114 | 28 | 460 | |
| Jean‐Charles Soria | 286 | 271 | 106 | 20 | 487 |
All Works
Login with ORCID to disown or claim papers
Loading papers...